文献速递胃肠动力与功能性疾病

促分泌剂治疗便秘型肠易激综合征的疗效:系统评价与网络Meta分析

Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis.
PubMed 文献 · Gastroenterology · 2018-08-23

该系统评价与网络Meta分析检索截至2018年6月的多个数据库,纳入15项随机对照试验、共8462例便秘型肠易激综合征(IBS-C)成人患者,比较促分泌剂的疗效与安全性。利那洛肽、鲁比前列酮、普卡那肽和替纳帕诺均优于安慰剂,多数终点的疗效在各药物与剂量间相似;数据仅提取至12周,长期相对疗效未知。

要点

  • 利那洛肽、鲁比前列酮、普卡那肽和替纳帕诺治疗IBS-C均优于安慰剂。
  • 利那洛肽290 μg每日1次在多个终点疗效排名第一;替纳帕诺50 mg每日2次在改善腹胀方面排名第一。
  • 普卡那肽6 mg每日1次安全性排名第一;除鲁比前列酮8 μg每日2次外,所有药物腹泻均显著更常见。

核心结论

  • 在IBS-C促分泌剂的随机对照试验网络分析中,所有药物均优于安慰剂,多数终点上各药物与剂量的疗效相似。
  • 数据仅提取至12周时间点,因此这些药物的长期相对疗效未知。

研究设计与样本

  • 系统评价与网络Meta分析,检索MEDLINE、EMBASE、EMBASE Classic和Cochrane对照试验中心注册库至2018年6月。
  • 纳入15项评估促分泌剂治疗成人IBS-C疗效的随机对照试验,共8462例患者。
  • 纳入试验报告对治疗总体反应的二分类评估,数据采用随机效应模型合并,并按P评分对治疗排序。

主要发现

  • 利那洛肽、鲁比前列酮、普卡那肽和替纳帕诺在治疗IBS-C方面优于安慰剂。
  • 利那洛肽(290 μg每日1次)在美国食品药品监督管理局推荐的IBS-C试验终点、各试验主要终点、腹痛和完全自发排便方面疗效排名第一。
  • 替纳帕诺(50 mg每日2次)在减少腹胀方面排名第一。
  • 与安慰剂相比,利那洛肽(290 μg和500 μg每日1次)和普卡那肽(3 mg每日1次)的不良事件总数显著更多。
  • 普卡那肽6 mg每日1次安全性排名第一;除鲁比前列酮(8 μg每日2次)外,所有药物腹泻均显著更常见,接受鲁比前列酮的患者恶心显著更常见。

关键数值与推荐

  • 利那洛肽290 μg每日1次在FDA推荐的IBS-C试验终点、各试验主要终点、腹痛和完全自发排便方面疗效排名第一。
  • 替纳帕诺50 mg每日2次在减少腹胀方面排名第一。
  • 普卡那肽6 mg每日1次安全性排名第一。
  • 与安慰剂相比,利那洛肽290 μg和500 μg每日1次及普卡那肽3 mg每日1次的不良事件总数显著更多。
  • 除鲁比前列酮8 μg每日2次外,所有药物腹泻均显著更常见;接受鲁比前列酮的患者恶心显著更常见。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 数据仅在12周时间点提取,因此这些药物的长期相对疗效未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Several secretagogues have been approved for the treatment of irritable bowel syndrome with constipation (IBS-C). However, their relative efficacy is unclear because there have been no head-to-head randomized controlled trials. We conducted a network meta-analysis to compare their efficacies in patients with IBS-C. METHODS: We searched MEDLINE, EMBASE, EMBASE Classic, and the Cochrane Central Register of Controlled Trials through June 2018 to identify randomized controlled trials assessing the efficacy of secretagogues in adults with IBS-C. Trials included in the analysis reported a dichotomous assessment of overall response to therapy, and data were pooled using a random-effects model. Efficacy and safety of secretagogues were reported as a pooled relative risk with 95% confidence interval to summarize the effect of each comparison tested, and treatments were ranked according to their P score. RESULTS: We identified 15 eligible randomized controlled trials of secretagogues that included 8462 patients. Linaclotide, lubiprostone, plecanatide, and tenapanor were superior to placebo for the treatment of IBS-C. Linaclotide (290 μg once daily) was ranked first in efficacy based on the end point recommended by the Food and Drug Administration for trials in IBS-C, the primary end point used in each trial, abdominal pain, and complete spontaneous bowel movements. Tenapanor (50 mg twice daily) was ranked first for decreasing bloating. Total numbers of adverse events were significantly larger with linaclotide (290 and 500 μg once daily) and plecanatide (3 mg once daily) compared with placebo. However, plecanatide 6 mg once daily ranked first for safety. Diarrhea was significantly more common with all drugs, except lubiprostone (8 μg twice daily). Nausea was significantly more common in patients who received lubiprostone. CONCLUSIONS: In a network analysis of randomized controlled trials of secretagogues for IBS-C, we found all drugs to be superior to placebo. Efficacy was similar among individual drugs and dosages for most end points. However, data were extracted at the 12-week time point, so the long-term relative efficacy of these drugs is unknown.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Black CJ, Burr NE, Quigley EMM, et al. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. Gastroenterology. 2018. PMID: 30144426. doi:10.1053/j.gastro.2018.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。